Advertisement

Acta Diabetologica

, Volume 56, Issue 5, pp 501–504 | Cite as

The STOP DIABETES study: when prevention works

  • Aldo BonaventuraEmail author
  • Fabrizio Montecucco
Perspectives

Abstract

Although many drugs are now available, a large effort is still needed to prevent diabetes. The STOP DIABETES study evaluated individuals at risk for type 2 diabetes (T2D) by a 2-h 75-g oral glucose tolerance test (OGTT). Based on the three main defective physiological responses, subjects were stratified as at low, intermediate, or high risk, and treated accordingly with lifestyle modifications and drugs. Participants at intermediate and high risk experienced the greatest reduction of T2D conversion. Interestingly, a group of individuals developing T2D presented a normal glucose tolerance at baseline, but a 1-h plasma glucose concentration > 155 mg/dL. These results are critical as prediabetes can increase the incidence of cardiovascular disease. Considering the timeframe between the first defects in glucose metabolism and the manifestation of diabetes complications, the effort to tackle the glycemic impairment as soon as possible represents an outstanding task to reduce the incidence of diabetes. Ideally, the earlier glycemic alterations are recognized, the lesser armamentarium needs to be used, and the lower is the expense in terms of drugs, complications, and related events and costs. Finally, a wealth of studies clearly demonstrated the importance of 1-h plasma glucose concentration, which has been proposed as an adjunctive diagnostic tool to detect prediabetes earlier. In conclusion, by an OGTT, a lot of individuals at risk for T2D may be detected when the central role for the 1-h plasma glucose concentration is also considered. Consequently, these subjects would be treated early and with less drugs and delay T2D complications.

Keywords

Diabetes Prediabetes 1-h post-load plasma glucose OGTT Prevention 

Notes

Acknowledgements

This study was supported by a grant from the Rete Cardiologica from the Italian Ministry of Health to Fabrizio Montecucco.

Author contributions

AB conceived and wrote the manuscript draft. FM read critically and improved the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    Zimmet PZ (2017) Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol 3:1.  https://doi.org/10.1186/s40842-016-0039-3 CrossRefGoogle Scholar
  2. 2.
    Carbone S, Dixon DL, Buckley LF, Abbate A (2018) Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review. Mayo Clin Proc 93(11):1629–1647.  https://doi.org/10.1016/j.mayocp.2018.07.018 CrossRefGoogle Scholar
  3. 3.
    Armato JP, DeFronzo RA, Abdul-Ghani M, Ruby RJ (2018) Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol 6(10):781–789.  https://doi.org/10.1016/S2213-8587(18)30234-1 CrossRefGoogle Scholar
  4. 4.
    Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773–795.  https://doi.org/10.2337/db09-9028 CrossRefGoogle Scholar
  5. 5.
    Nathan DM (2002) Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347(17):1342–1349.  https://doi.org/10.1056/NEJMcp021106 CrossRefGoogle Scholar
  6. 6.
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343–1350.  https://doi.org/10.1056/NEJM200105033441801 CrossRefGoogle Scholar
  7. 7.
    Investigators DT, Gerstein HC, Yusuf S et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096–1105.  https://doi.org/10.1016/S0140-6736(06)69420-8 CrossRefGoogle Scholar
  8. 8.
    Bartoli E, Fra GP, Carnevale Schianca GP (2011) The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med 22(1):8–12.  https://doi.org/10.1016/j.ejim.2010.07.008 CrossRefGoogle Scholar
  9. 9.
    Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research G (2009) Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 32(9):1583–1588.  https://doi.org/10.2337/dc09-0523 CrossRefGoogle Scholar
  10. 10.
    Lind M, Tuomilehto J, Uusitupa M et al (2014) The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS One 9(10):e109506.  https://doi.org/10.1371/journal.pone.0109506 CrossRefGoogle Scholar
  11. 11.
    Huang Y, Cai X, Mai W, Li M, Hu Y (2016) Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 355:i5953.  https://doi.org/10.1136/bmj.i5953 CrossRefGoogle Scholar
  12. 12.
    Ford ES, Zhao G, Li C (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55(13):1310–1317.  https://doi.org/10.1016/j.jacc.2009.10.060 CrossRefGoogle Scholar
  13. 13.
    Hou X, Liu J, Song J et al (2016) Relationship of hemoglobin a1c with beta cell function and insulin resistance in newly diagnosed and drug naive type 2 diabetes patients. J Diabetes Res 2016:8797316.  https://doi.org/10.1155/2016/8797316 CrossRefGoogle Scholar
  14. 14.
    Abdul-Ghani MA, Puckett C, Triplitt C et al (2015) Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab 17(3):268–275.  https://doi.org/10.1111/dom.12417 CrossRefGoogle Scholar
  15. 15.
    Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med J Br Diabet Assoc 19(9):708–723CrossRefGoogle Scholar
  16. 16.
    Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA (2008) One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31(8):1650–1655.  https://doi.org/10.2337/dc08-0225 CrossRefGoogle Scholar
  17. 17.
    Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L (2009) Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32(2):281–286.  https://doi.org/10.2337/dc08-1264 CrossRefGoogle Scholar
  18. 18.
    Fiorentino TV, Marini MA, Succurro E et al (2018) One-hour postload hyperglycemia: implications for prediction and prevention of type 2 diabetes. J Clin Endocrinol Metab 103(9):3131–3143.  https://doi.org/10.1210/jc.2018-00468 CrossRefGoogle Scholar
  19. 19.
    Fiorentino TV, Marini MA, Andreozzi F et al (2015) One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose. J Clin Endocrinol Metab 100(10):3744–3751.  https://doi.org/10.1210/jc.2015-2573 CrossRefGoogle Scholar
  20. 20.
    Alyass A, Almgren P, Akerlund M et al (2015) Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58(1):87–97.  https://doi.org/10.1007/s00125-014-3390-x CrossRefGoogle Scholar
  21. 21.
    Abdul-Ghani MA, Abdul-Ghani T et al (2011) Role of glycated hemoglobin in the prediction of future risk of T2DM. J Clin Endocrinol Metab 96(8):2596–2600.  https://doi.org/10.1210/jc.2010-1698 CrossRefGoogle Scholar
  22. 22.
    Marini MA, Succurro E, Frontoni S et al (2012) Insulin sensitivity, beta-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35(4):868–872.  https://doi.org/10.2337/dc11-2181 CrossRefGoogle Scholar
  23. 23.
    Manco M, Panunzi S, Macfarlane DP et al (2010) One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33(9):2090–2097.  https://doi.org/10.2337/dc09-2261 CrossRefGoogle Scholar
  24. 24.
    Jagannathan R, Sevick MA, Fink D et al (2016) The 1-hour post-load glucose level is more effective than HbA1c for screening dysglycemia. Acta Diabetol 53(4):543–550.  https://doi.org/10.1007/s00592-015-0829-6 CrossRefGoogle Scholar
  25. 25.
    Paddock E, Hohenadel MG, Piaggi P et al (2017) One-hour and two-hour postload plasma glucose concentrations are comparable predictors of type 2 diabetes mellitus in Southwestern Native Americans. Diabetologia 60(9):1704–1711.  https://doi.org/10.1007/s00125-017-4332-1 CrossRefGoogle Scholar
  26. 26.
    Bergman M, Manco M, Sesti G et al (2018) Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). Diabetes Res Clin Pract 146:18–33.  https://doi.org/10.1016/j.diabres.2018.09.017 CrossRefGoogle Scholar
  27. 27.
    Fiorentino TV, Sesti F, Andreozzi F et al (2016) One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden. Atherosclerosis 253:61–69.  https://doi.org/10.1016/j.atherosclerosis.2016.08.020 CrossRefGoogle Scholar
  28. 28.
    Fiorentino TV, Succurro E, Andreozzi F, Sciacqua A, Perticone F, Sesti G (2019) One-hour post-load hyperglycemia combined with HbA1c identifies individuals with higher risk of cardiovascular diseases: cross-sectional data from the CATAMERI study. Diabetes Metab Res Rev 35(2):e3096.  https://doi.org/10.1002/dmrr.3096 CrossRefGoogle Scholar
  29. 29.
    Jagannathan R, Buysschaert M, Medina JL et al (2018) The 1-h post-load plasma glucose as a novel biomarker for diagnosing dysglycemia. Acta Diabetol 55(6):519–529.  https://doi.org/10.1007/s00592-018-1105-3 CrossRefGoogle Scholar
  30. 30.
    Liu K, Dyer AR, Vu TH et al (2005) One-hour postload plasma glucose in middle age and Medicare expenditures in older age among nondiabetic men and women: the Chicago Heart Association Detection Project in Industry. Diabetes Care 28(5):1057–1062CrossRefGoogle Scholar
  31. 31.
    Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373(9682):2215–2221.  https://doi.org/10.1016/S0140-6736(09)60619-X CrossRefGoogle Scholar
  32. 32.
    UK Prospective Diabetes Study 16 (1995) Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 44(11):1249–1258CrossRefGoogle Scholar
  33. 33.
    Meier JJ, Bonadonna RC (2013) Role of reduced beta-cell mass versus impaired beta-cell function in the pathogenesis of type 2 diabetes. Diabetes Care 36(Suppl 2):S113–S119.  https://doi.org/10.2337/dcS13-2008 CrossRefGoogle Scholar
  34. 34.
    Zimmet P, Alberti KG (2018) What and when is diabetes? A devil’s advocate perspective on contemporary controversies in diabetes criteria and classification. J Diabetes 10(10):804–807.  https://doi.org/10.1111/1753-0407.12793 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  1. 1.First Clinic of Internal Medicine, Department of Internal MedicineUniversity of GenoaGenoaItaly
  2. 2.Division of Cardiology, Department of Internal Medicine, Pauley Heart CenterVirginia Commonwealth UniversityRichmondUSA
  3. 3.First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR)University of GenoaGenoaItaly
  4. 4.IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular NetworkGenoaItaly

Personalised recommendations